• Publications
  • Influence
Evaluation of the efficacy and tolerability of fixed-dose combination therapy of azilsartan and amlodipine besylate in Japanese patients with grade I to II essential hypertension.
This study found that the FDC of AZI/AML 20/5 mg and 20/2.5 mg exhibited greater antihypertensive effects compared with each monotherapy and was tolerable to Japanese patients with grade 1 to 2 essential hypertension. Expand
Effect of TAK‐085 on Low‐density Lipoprotein Particle Size in Patients with Hypertriglyceridemia: A Double‐blind Randomized Clinical Study
TAK‐085 produced a favorable shift in the LDL particle size in Japanese patients with hypertriglyceridemia, and increased the LDL cholesterol/apolipoprotein B ratios and the mean diameter of LDL particles from baseline to the end of the study. Expand
A Randomized, Single‐Center, Double‐Blind, Placebo‐Controlled Multiple‐Dose Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Imarikiren in Healthy Adult Nonelderly and
Assessment of the safety and pharmacokinetics/pharmacodynamics of multiple oral administrations of imarikiren in healthy nonelderly and elderly Japanese male subjects found it safe and well tolerated with no drug accumulation and strong and sustained suppression of plasma renin activity. Expand
Pharmacokinetics, Pharmacodynamics and Safety of a Single Dose of Imarikiren, a Novel Renin Inhibitor, in Healthy Male Subjects
Plasma active renin concentration increased, reaching a maximum at approximately 6 hr, in a nearly dose‐dependent manner, and there was a generally linear relationship between dose and area under the plasma concentration–time curve (0 to infinity) or maximum plasma concentration of imarikiren. Expand
Pharmacokinetics and Safety After a Single Dose of Imarikiren in Subjects with Renal or Hepatic Impairment
RI and HI are associated with limited changes in imarikiren pharmacokinetics and Imarikirens was safe and well-tolerated, regardless of the severity of RI or HI. Expand
Efficacy and Safety of Imarikiren in Patients with Type 2 Diabetes and Microalbuminuria: A Randomized, Controlled Trial.
Imarikiren resulted in a dose-dependent improvement in albuminuria compared with placebo, and it was well tolerated in patients with type 2 diabetes mellitus and microalbuminuria. Expand